Schedule 13G ownership disclosure
CytomX Therapeutics Inc
Common Stock, par value $0.00001 per share · CUSIP: 23284F105
Event date: 2025-03-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- TANG CAPITAL MANAGEMENT, LLC
Shares: 6,717,825.00 · Class: 8.4%
- KEVIN TANG
Shares: 6,717,825.00 · Class: 8.4%
- TANG CAPITAL PARTNERS, LP
Shares: 4,964,773.00 · Class: 6.2%
- TANG CAPITAL PARTNERS INTERNATIONAL, LP
Shares: 1,753,052.00 · Class: 2.2%
- TANG CAPITAL PARTNERS III, INC
Shares: 0.00 · Class: 0.0%
- TANG CAPITAL PARTNERS IV, INC
Shares: 0.00 · Class: 0.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001214659-25-007872
- Form type
- SCHEDULE 13G/A
- Filer
- CytomX Therapeutics, Inc.
- CIK
- CIK 1501989
- Filed
- May 15, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership